FDA reviews Merck & Co's Keytruda in new 'tumour agnostic' u...

Merck & Co’s Keytruda cancer immunotherapy could be set for another indication, which could open up for use in all cancer patients whose tumours have a certain genetic biomarker.

Pharma steps up as coronavirus cases soar to 400,000-plus

Merck’s chronic cough drug gefapixant clears phase 3 test

WebMD buys employee wellbeing platform StayWell from Merck

Health information firm WebMD has bought The StayWell Company, a subsidiary of US-based Merck & Co.

AZ's cediranib falls short again in ovarian cancer combinati...

AstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it did not improve survival compared with chemotherapy in advanced ovarian cancer, in

Merck’s digital chief Scholefield jumps ship to Marriott